Second Opinions From Tumor Board Often Changes Treatment Decisions

October 22, 2018 | Tumor Conferences

Second opinions from a multi-disciplinary tumor board (MTB) at a National Cancer Institute (NCI)-designated cancer center changed the diagnosis of 43 percent of breast cancer patients, according to a new study published in the Annals of Surgical Oncology. Despite documented evidence of MTBs, many patients with breast cancer still receive care without MTB review.

While tumor board meetings have shown compelling results for patients undergoing cancer treatment, they are often unorganized which results in fewer patients being included. The HealthMyne Tumor Conference Module can significantly reduce the effort to prepare patients for tumor conferences and makes presenting the patient a breeze too.

The full article is available here.